Video: Are we looking at the proper endpoints?

In the final video of this part of the discussion, Dr. Inna Slutsky asks the question: instead of exclusively focusing on the primary toxicity-causing molecules in AD, should we also be trying to understand the compensatory mechanisms which may stave off disease pathogenesis?

Like Comment
Nature Neuroscience presents a panel discussion by several leaders in the field of Alzheimer’s disease (AD) research in which we take a critical look at the many (sometimes seemingly contradictory) facets of AD pathogenesis and progression. In this first set of videos, the panel examines the Amyloid hypothesis: Given the fact that plaque/Aβ load does not always temporally correlate with dementia in human patients as well as the apparent failure of some recent anti-Aβ therapies, is it time to re-think our over-reliance on the Aβ hypothesis?

Tim Spencer

Senior Editor, Nature Neuroscience

Tim Spencer received his PhD from the City University of New York, where he studied the signaling mechanisms which underlie the promotion of axonal growth and regeneration following injury in the laboratory of Marie Filbin. He then moved to the laboratory of Chris Henderson at Columbia University, where he examined molecular markers of postnatal motor neuron maturation and elements of neurodegenerative diseases such as ALS and SMA. His research interests include neuronal development and maturation, axonal guidance and models of neuronal disease and dysfunction. Tim joined the editorial team of Nature Neuroscience in March of 2011, where he handles many of the manuscripts on neural development and neurogenesis, neurodegeneration, neuroinflammation and neuroimmune interactions, myelination/remyelination, molecular and cellular pathways, and "brain cancer" (glioblastoma, etc.).